

Rapport d'analyses statistiques

Axelle Dupont, sbim, Hopital Saint Louis, Paris

November 13, 2017

Contents

1	Objectives	4
2	Methods	4
3	Results	5
3.1	Descriptive results	5
3.1.1	Patients characteristics	5
3.1.2	Treatments before alloSCT	6
3.1.3	Transplant conditions	7
3.1.4	Post-AlloSCT Response	10
3.2	Survival analysis in all patients	14
3.2.1	Overall survival, EFS and GRFS	14
3.2.2	TRM and cause of death	19
3.3	OS et PFS après une cgvhhd	22
3.4	Progressive disease analysis	23
3.5	CR1 analysis	26
3.6	Survival analysis after a complete remission post alloSCT	30
3.7	Univariate Analysis and multivariate analysis	35

List of Tables

1	Patients characteristics	6
2	Treatments before alloSCT	6
3	Transplant conditions	9
4	Post-AlloSCT Response	11
5	Characteristics according to conditioning MAC vs MNA/RIC	13
6	Univariate analysis of 5 years OS survival	36
7	Multivariate analysis of 5 years OS (stratified on the delay between diagnosis and alloSCT)	36
8	Univariate analysis of 5 years GRFS	38
9	Multivariate analysis of 5 years GRFS	38
10	Univariate analysis of 5 years EFS	40
11	Multivariate analysis of 5 years EFS	40
12	Univariate analysis of 5 years cause specific mortality : HSCT related	42
13	Multivariate analysis of 5 years cause specific mortality : HSCT related (stratified on numbers of lines before alloSCT)	42
14	Propensity score for 5 years OS	43
15	Propensity score for 5 years EFS	43
16	Propensity score for 5 years HCST related death	43
17	Propensity score for 5 years relapse relapse (competitive risks)	43

List of Figures

1	Overall survival	14
2	CIF of relapse or progression and death without relapse or progression	15
3	CIF of relapse or progression and death without relapse or progression according to conditioning	16
4	EFS and GRFS	17
5	EFS according to conditioning	18
6	TRM	19
7	TRM according to conditioning	20
8	CIF of Related HSCT Death and Non-related HSCT Death	21
9	CIF of GVHD and Death without GVHD (acute or chronic)	22
10	OS after cgvh in cgvh patients	23
11	OS in the group with progressive disease at graft	24
12	TRM in the group with progressive disease at graft	25
13	CIF of relapse or progression and death without relapse or progression in the group with progressive disease at graft	26
14	OS in the CR1 group	27
15	TRM in the CR1 group	28
16	CIF of relapse or progression and death without relapse or progression in the CR1 group	29

17	OS in patients with a complete remission post alloSCT	30
18	CIF of relapse and death without relapse (in patients with a complete remission post alloSCT)	31
19	RFS and EFS in patients with a complete remission post alloSCT	32
20	CIF of Related HSCT Death and Non-related HSCT Death (in patients with a complete remission post alloSCT)	33
21	CIF of GVHD and Death without GVHD (acute or chronic)(in patients with a complete remission post alloSCT)	34

1 Objectives

The primary objective of the study was to assess the survival, the risk of relapse and GVHD of patients who underwent allogenic stem-cell transplantation (alloSCT) for aggressive T-cell lymphomas. The second objective was to determine the variables associated with these outcomes.

2 Methods

A retrospective analysis was conducted. A descriptive analysis of the variables recorded was performed. Different endpoints were defined : death, Event Free Survival (EFC), GRFS. GRFS was defined as death, progression/relapse, grade 3-4 acute GVHD or extensive chronic GVHD.

Survival curves were estimated using Kaplan-Meier product-limit estimator. Competing risk survival analysis methods were applied to estimate the cumulative incidence (CIF) of developing events over time from alloSCT. These methods allow for the fact that a patient may experience an event which is different from that of interest. These events are known as competing risk events, and may preclude the onset of the event of interest, or may modify the probability of the onset of that event. In particular, a transplanted patient may die before a relapse occurs.

Factors associated with overall survival were analyzed using Cox proportional hazards models. The proportional hazards assumption was checked by examination of Schoenfeld residuals. Occurrence of a grade 3-4 acute GVHD or chronic GVHD was treated as a time dependent covariable. For the different endpoints, univariable analyses were first carried out, then a multivariable analysis was used where all factors with P-value < 0.05 in the univariable analyses were considered. If needed, factors were then sequentially removed from the adjusted model based on the AIC criteria.

Propensity score was constructed, excluded patients that cannot receive MAC : patients aged more than 50 years, with a Karnofsky score under 70, with a previous autoSCT or with a source of graft different from BM.

3 Results

3.1 Descriptive results

285 patients were initially selected. We excluded 1 patient that underwent two alloSCT. The final analysis was performed on 284 patients and 284 grafts.

3.1.1 Patients characteristics

Parameters	Values	N	Statistics*
		284	
Patient sex	Female	93	32.75 %
	Male	191	67.25 %
Age at diagnosis		284	46.5 [36;55] (15;68)
Stage at diagnosis	I	13	6.47 %
	II	17	8.46 %
	III	45	22.39 %
	IV	126	62.69 %
	NA	83	
Subtypes	AITL	82	28.87 %
	ALCL ALK-	20	7.04 %
	ALCL ALK?	2	0.7 %
	ALCL ALK+	21	7.39 %
	ATLL	16	5.63 %
	EATL	3	1.06 %
	HS	12	4.23 %
	LGL	1	0.35 %
	NK leukemia	1	0.35 %
	NK/T nasal	16	5.63 %
Subtypes	NOS	110	38.73 %
	NOS	110	38.73 %
	AITL	82	28.87 %
	ALCL	43	15.14 %
	ATLL	16	5.63 %
	NK/T nasal	16	5.63 %
Centres	Others	17	5.99 %
	angers	8	2.82 %
	Becquerel[941]	4	1.41 %
	C.H.R.U Brest[659]	2	0.7 %
	caen	4	1.41 %
	CHU clermont ferrand	7	2.46 %
	Geneve	6	2.11 %
	Gustave Roussy[666]	3	1.06 %
	H A Michallon[270]	5	1.76 %

H Bretonneau[272]	3	1.06 %
H Charles Nicolle[932]	1	0.35 %
H Claude Huriez[277]	8	2.82 %
H de l'ARCHET I[523]nice	3	1.06 %
H E Herriot[671]	5	1.76 %
H Haut-Leveque[267]	31	10.92 %
H Hautepierre[672]	11	3.87 %
H Jean Minjoz[233]	5	1.76 %
H La Miletrie[264]	5	1.76 %
H Mondor Hematol[252]	4	1.41 %
H Necker[160]	9	3.17 %
H Percy[665]	4	1.41 %
H Purpan[624]	8	2.82 %
H Sud/Pontchaillou[661]	7	2.46 %
H Sud[955]	1	0.35 %
Hotel Dieu[253]	32	11.27 %
liege	8	2.82 %
limoges	3	1.06 %
montpellier	10	3.52 %
nancy	1	0.35 %
Paoli Calmettes[230]	39	13.73 %
Pellegrin-Enfants[978]	1	0.35 %
Pitie-Salpetriere[262]	8	2.82 %
St Antoine[775]	10	3.52 %
St Etienne[250]	4	1.41 %
St Louis[207]	24	8.45 %

Table 1: Patients characteristics

3.1.2 Treatments before alloSCT

Parameters	Values	N	Statistics*
		284	
Previous auto	No	191	67.25 %
	Yes	93	32.75 %
Programme auto allo	No	257	90.49 %
	Yes	27	9.51 %
First graft relapse	No	219	77.11 %
	Yes	65	22.89 %

Table 2: Treatments before alloSCT

3.1.3 Transplant conditions

Parameters	Parameters	N	n(%) med[Q1;Q3](min,m
		284	
Age at graft		284	49.5 [38;57] (16;69)
Donor age		263	28 [18;39] (1;54)
Donor sex	Female	114	40.71 %
	Male	166	59.29 %
	NA	4	
Delay diagnosis and allo SCT		284	378.5 [213.2;710.8] (89;9
>12 months delay	NO	149	52.46 %
	Yes	135	47.54 %
Disease status at transplant	CR	175	61.84 %
	PR	76	26.86 %
	PD	32	11.31 %
	NA	1	
Disease status at transplant	CR (?)	7	2.47 %
	CR1	94	33.22 %
	CR2	61	21.55 %
	CR3	13	4.59 %
	PD	32	11.31 %
	PR (?)	13	4.59 %
	PR1	39	13.78 %
	PR2	18	6.36 %
	PR3	5	1.77 %
	PR4	1	0.35 %
	NA	1	
Karnofsky score		263	90 [80;100]
Karnofsky score	100	92	34.98 %
	40	1	0.38 %
	50	4	1.52 %
	60	1	0.38 %
	70	9	3.42 %
	80	70	26.62 %
	90	86	32.7 %
	NA	21	
Karnofsky score	100	92	34.98 %
	Unable to carry on normal activity	15	5.7 %
	90-80	156	59.32 %
	NA	21	
No of lines before alloSCT		254	2 [1;3] (1;9)
No of lines before alloSCT	1	73	28.74 %
	2	92	36.22 %

	3	65	25.59 %
	>=4	24	9.45 %
	NA	30	
No of lines before alloSCT	>2	89	35.04 %
	1 or 2	165	64.96 %
	NA	30	
HLA match	HLA mismatched	53	18.66 %
	HLA matched	231	81.34 %
HLA match	Alternative donnors	53	18.66 %
	Identical sibling	128	45.07 %
	Matched unrelated	103	36.27 %
HLA match	Identical sibling	128	45.07 %
	Matched unrelated	103	36.27 %
	Mismatched relative	7	2.46 %
	Mismatched unrelated	13	4.58 %
	Unrelated CB	33	11.62 %
Sex of donnor/patient	Others	205	73.48 %
	F/M	74	26.52 %
	NA	5	
CMV serostatus of donnor/patient	neg/neg	91	32.5 %
	Others	189	67.5 %
	NA	4	
Source of stem cells	BM	49	17.25 %
	CB	33	11.62 %
	PB	202	71.13 %
TBI	No	161	56.69 %
	Yes	123	43.31 %
conditioning Intensity	MAC	106	38.13 %
	NMA	27	9.71 %
	RIC	145	52.16 %
	NA	6	
Conditioning	BEAM	1	0.36 %
	BEAM + Campath	1	0.36 %
	BU CY	4	1.42 %
	BU CY + FLU+ ATG	1	0.36 %
	BU CY ATG	1	0.36 %
	EDX ATG	0	0 %
	ENX TBI 2gray	1	0.36 %
	FLU ATG	3	1.07 %
	FLU BU 1+ ATG	3	1.07 %
	FLU BU 2	1	0.36 %
	FLU BU 2+ ATG	73	25.98 %
	FLU BU 3+ ATG	21	7.47 %

	FLU BU 4+ ATG	10	3.56 %
	FLU BU EDX	8	2.85 %
	FLU BU EDX +ATG	6	2.14 %
	FLU EDX	1	0.36 %
	FLU EDX ATG	3	1.07 %
	FLU EDX MEL	1	0.36 %
	FLU ENX TBI 2gray	24	8.54 %
	FLU ENX TBI 4gray	2	0.71 %
	FLU ENX TBI 6gray	1	0.36 %
	FLU ENX TBI 6gray + campath	1	0.36 %
	FLU MEL	12	4.27 %
	FLU MEL + campath	4	1.42 %
	FLU MEL + Campath	1	0.36 %
	FLU MEL ATG	1	0.36 %
	FLU MEL TBI 2gray	1	0.36 %
	FLU TBI 2gray	21	7.47 %
	FLU TBI 2gray ATG	1	0.36 %
	FLU Tbi 8 gray	1	0.36 %
	MEL 140 TBI 10 gray	1	0.36 %
	MEL TBI VP16	1	0.36 %
	TB2F	2	0.71 %
	TBI 12 gray	1	0.36 %
	TBI 2gray	1	0.36 %
	TBI EDX	49	17.44 %
	TBI EDX +ATG	11	3.91 %
	TBI EDX FLU	5	1.78 %
	Thiotepa etoposide TBI12 gray	1	0.36 %
	NA	3	
Cells manipulation	No	275	97.86 %
	Yes	6	2.14 %
	NA	3	
Depletion	No	275	98.57 %
	Partial T depletion	4	1.43 %
	NA	5	
No of donnors	1	261	91.9 %
	2	23	8.1 %

Table 3: Transplant conditions

3.1.4 Post-AlloSCT Response

Parameters	Values	N	Statistics*
		284	
Agvhd	No	141	49.65 %
	Yes	143	50.35 %
Agvhd grade	No aGvHD present (Grade 0)	141	49.65 %
	Grade I	49	17.25 %
	Grade II	46	16.2 %
	Grade III	24	8.45 %
	Grade IV	17	5.99 %
	Present, grade unknown	7	2.46 %
Cgvhd	Early death	41	14.44 %
	no	146	51.41 %
	yes	97	34.15 %
Cgvhd grade	Early death (100D)	41	14.44 %
	Extensive	38	13.38 %
	Limited	55	19.37 %
	No cGvh	146	51.41 %
	grade unknown	4	1.41 %
Engrafted	Early death (30D)	5	1.76 %
	Engrafted	271	95.42 %
	Lost graft	2	0.7 %
	No engraftment	6	2.11 %
Cause of death	HSCT-GVHD	21	19.63 %
	HSCT-GVHD + infection	3	2.8 %
	HSCT-infection	27	25.23 %
	HSCT-toxicity	4	3.74 %
	HSCT related	3	2.8 %
	HSCT related ILD	1	0.93 %
	HSCT related MAT	1	0.93 %
	HSCT related MOF	2	1.87 %
	HSCT related MVO	1	0.93 %
	HSCT related pneumopathie interstitielle	2	1.87 %
	HSCT related PTLN	1	0.93 %
	HSCT related SDRA	1	0.93 %
	Other	1	0.93 %
	Relapse or progression of original disease	37	34.58 %
	Secondary malignancy	1	0.93 %
	Unknown	1	0.93 %
	NA	177	
Best reponse after SCT	CR	245	86.88 %
	Not evaluable	4	1.42 %

Relapse/progression	Not evaluated	3	1.06 %
	PD	14	4.96 %
	PR	16	5.67 %
	NA	2	
	Continuous progression	28	9.93 %
	No	217	76.95 %
	Non applicable	3	1.06 %
	Yes	34	12.06 %
	NA	2	

Table 4: Post-AlloSCT Response

Parameters	Parameters	N	n(%) med[Q1;Q3](min,max)	N	n(%) med[Q1;Q3](min,max)	p
		N	Statistics*	N	Statistics*	p-value
		106	MAC	172	RIC/NMA	
Age greffe		106	40 [34;51] (16;64)	172	54 [43;59.25] (19;69)	<0.0001
Nbr de lignes		98	2 [1;3] (1;5)	151	2 [2;3] (1;9)	0.006
Nbr de lignes	>2	28	28.57 %	61	40.4 %	0.077
	1 or 2	70	71.43 %	90	59.6 %	
	NA	8		21		
Nbr de lignes	1	33	33.67 %	36	23.84 %	0.053
	2	37	37.76 %	54	35.76 %	
	3	24	24.49 %	41	27.15 %	
	>=4	4	4.08 %	20	13.25 %	
	NA	8		21		
Autogreffe avant	0	89	83.96 %	96	55.81 %	<0.0001
	1	17	16.04 %	76	44.19 %	
Statut de la maladie	CR	58	54.72 %	114	66.67 %	0.015
	PR	39	36.79 %	36	21.05 %	
	PD	9	8.49 %	21	12.28 %	
	NA	0		1		
Karnofsky	100	39	38.24 %	53	33.76 %	0.33
	Unable to carry on normal activity	8	7.84 %	7	4.46 %	
	90-80	55	53.92 %	97	61.78 %	
	NA	4		15		
Stade dia	I	5	6.02 %	8	6.96 %	0.16
	II	3	3.61 %	13	11.3 %	
	III	17	20.48 %	28	24.35 %	
	IV	58	69.88 %	66	57.39 %	
	NA	23		57		
Delai dia-allo (mois)		106	289 [184;506.5] (91;6243)	172	436 [264.8;874.5] (109;9684)	0.0003
Delai dia allo sup a 12 mois	NO	42	39.62 %	106	61.63 %	0.0006

Donneur	Yes	64	60.38 %	66	38.37 %	0.035
	HLA mismatched	13	12.26 %	40	23.26 %	
Sexe d/p	HLA matched	93	87.74 %	132	76.74 %	0.54
	Others	80	76.19 %	121	72.02 %	
	F/M	25	23.81 %	47	27.98 %	
CMV d/p	NA	1		4		0.024
	neg/neg	43	40.95 %	46	27.06 %	
	Others	62	59.05 %	124	72.94 %	
Origine cellule	NA	1		2		<0.0001
	BM	35	33.02 %	13	7.56 %	
	CB	8	7.55 %	25	14.53 %	
TBI	PB	63	59.43 %	134	77.91 %	
	No	37	34.91 %	119	69.19 %	
	Yes	69	65.09 %	53	30.81 %	

Table 5: Characteristics according to conditionning MAC vs MNA/RIC

3.2 Survival analysis in all patients

3.2.1 Overall survival, EFS and GRFS

Median follow-up was 20.18 (range 0.03 to 112.83). OS at 1 year was 0.68 (95 % 0.62 - 0.73), was 0.64 (95 % 0.58 - 0.7) at 2 years. OS at 4 years was 0.57 (95 % 0.5 - 0.63).




Figure 1: Overall survival

CIF for relapse/progression at 1 years was 0.18 (95 % 0.13 - 0.23), at 2 years 0.19 (95 % 0.15 - 0.24). CIF for death without relapse or progression at 1 year was 0.19 (95 % 0.14 - 0.24), at 2 years 0.22 (95 % 0.17 - 0.27).




Figure 2: CIF of relapse or progression and death without relapse or progression




Figure 3: CIF of relapse or progression and death without relapse or progression according to conditionning

CIF of relapse or progression with MAC at 1 year : 0.19, was 0.23 at 2 years. CIF of relapse or progression with RIC/NMA at 1 year : 0.17, was 0.17 at 2 years.

EFS at 1 year was 0.63 (95 % 0.57 - 0.69), was 0.59 (95 % 0.53 - 0.65) at 2 years. EFS at 4 years was 0.52 (95 % 0.45 - 0.59).

Délai médian rechute : 94 jours.

GRFS at 1 year was 0.49 (95 % 0.44 - 0.56), was 0.47 (95 % 0.41 - 0.54) at 2 years.

GRFS at 4 years was 0.43 (95 % 0.37 - 0.5).




Figure 4: EFS and GRFS




Figure 5: EFS according to conditioning

EFS MAC : 1 year : 0.65 (95 % 0.56 - 0.75) 2 year : 0.59 (95 % 0.5 - 0.7)

EFS RIC/NMA : 1 year : 0.78 (95 % 0.72 - 0.85) 2 year : 0.73 (95 % 0.67 - 0.8)

3.2.2 TRM and cause of death

TRM at 1 year was 0.22 (95 % 0.27 - 0.17), was 0.24 (95 % 0.3 - 0.19) at 2 years. TRM at 4 years was 0.3 (95 % 0.37 - 0.24).




Figure 6: TRM




Figure 7: TRM according to conditionning

TRM MAC : 1 year : 0.18 (95 % 0.26 - 0.1) 2 year : 0.2 (95 % 0.28 - 0.11)

TRM RIC : 1 year : 0.22 (95 % 0.28 - 0.15) 2 year : 0.26 (95 % 0.32 - 0.18)




Figure 8: CIF of Related HSCT Death and Non-related HSCT Death

CIF for related HSCT death at 1 years was 0.2, at 2 years 0.23. CIF for non-related HSCT Death at 1 year was 0.12, at 2 years 0.13.




Figure 9: CIF of GVHD and Death without GVHD (acute or chronic)

3.3 OS et PFS après une cgvhhd

OS at 1 year after cgvhhd was 0.82 (95 % 0.74 - 0.91), was 0.74 (95 % 0.65 - 0.85) at 2 years




Figure 10: OS after cgvhhd in cgvhhd patients

PFS at 1 year after cgvhhd was 0.75 (95 % 0.64 - 0.85), was 0.66 (95 % 0.56 - 0.77) at 2 years

3.4 Progressive disease analysis

OS at 6 months in the group with progressive disease at graft was 0.65 (95 % 0.46 - 0.79). OS at 1 year in the group with progressive disease at graft was 0.51 (95 % 0.33 - 0.67), was 0.51 (95 % 0.33 - 0.67) at 2 years. OS at 4 years was 0.25 (95 % 0.08 - 0.47).




Figure 11: OS in the group with progressive disease at graft

TRM at 6 months in the group with progressive disease at graft was 0.18 (95 % 0.39 - 0.08)

TRM at 1 year in the group with progressive disease at graft was 0.27 (95 % 0.5 - 0.14), was 0.27 (95 % 0.5 - 0.14) at 2 years. TRM at 4 years was 0.54 (95 % 0.81 - 0.3).




Figure 12: TRM in the group with progressive disease at graft

CIF for relapse/progression in the group with progressive disease at 6 months was 0.31 (95 % 0.13 - 0.5)

CIF for relapse/progression in the group with progressive disease at 1 years was 0.31 (95 % 0.13 - 0.5), at 2 years 0.31 (95 % 0.13 - 0.5).




Figure 13: CIF of relapse or progression and death without relapse or progression in the group with progressive disease at graft

3.5 CR1 analysis

OS at 6 months was 0.77 (95 % 0.67 - 0.84) OS at 1 year was 0.68 (95 % 0.57 - 0.77), was 0.62 (95 % 0.51 - 0.72) at 2 years. OS at 4 years was 0.58 (95 % 0.46 - 0.69).




Figure 14: OS in the CR1 group

TRM at 6 months in the group with progressive disease was 0.15 (95 % 0.24 - 0.09)
 TRM at 1 year in the group with progressive disease was 0.23 (95 % 0.34 - 0.15), was
 0.27 (95 % 0.38 - 0.18) at 2 years. TRM at 4 years was 0.27 (95 % 0.38 - 0.18).




Figure 15: TRM in the CR1 group

CIF for relapse/progression in the group with progressive disease at 6 months was 0.11 (95 % 0.13 - 0.5). CIF for relapse/progression in the group with progressive disease at 1 years was 0.15 (95 % 0.13 - 0.5), at 2 years 0.16 (95 % 0.13 - 0.5).




Figure 16: CIF of relapse or progression and death without relapse or progression in the CR1 group

3.6 Survival analysis after a complete remission post alloSCT

245 patients with a complete remission were included.

OS at 1 year was 0.74 (95 % 0.68 - 0.8), was 0.7 (95 % 0.64 - 0.76) at 2 years. OS at 4 years was 0.62 (95 % 0.56 - 0.7).




Figure 17: OS in patients with a complete remission post alloSCT

CIF for relapse at 1 year was 0.12 (95 % 0.07 - 0.16), at 2 years 0.13 (95 % 0.09 - 0.18).
 CIF for death without relapse at 1 year was 0.19 (95 % 0.14 - 0.24), at 2 years 0.22 (95 % 0.17 - 0.28).




Figure 18: CIF of relapse and death without relapse (in patients with a complete remission post alloSCT)




Figure 19: RFS and EFS in patients with a complete remission post alloSCT




Figure 20: CIF of Related HSCT Death and Non-related HSCT Death (in patients with a complete remission post alloSCT)




Figure 21: CIF of GVHD and Death without GVHD (acute or chronic)(in patients with a complete remission post alloSCT)

3.7 Univariate Analysis and multivariate analysis

variable	Variable	HR	IC	pval	p
Age at graft		1.01	[0.99 - 1.02]	0.36	0.35
subtypes	NOS	1.00			0.46
	AITL	1.21	[0.75 - 1.97]	0.43	
	ALCL	1.16	[0.64 - 2.09]	0.63	
	ATLL	1.93	[0.93 - 4.01]	0.079	
	NK/T nasal	1.82	[0.85 - 3.93]	0.13	
	Others	1.55	[0.69 - 3.48]	0.29	
Delay between diag and allo SCT > 12 mo	NO	1.00			0.54
	Yes	0.89	[0.6 - 1.3]	0.54	
Stage at diagnosis	I	1.00			0.72
	II	0.49	[0.14 - 1.74]	0.27	
	III	0.79	[0.31 - 1.98]	0.61	
	IV	0.78	[0.33 - 1.81]	0.56	
Disease status at transplant	CR	1.00			0.027
	PR	0.97	[0.61 - 1.53]	0.89	
	PD	2.08	[1.24 - 3.49]	0.006	
Karnofsky score	100	1.00			0.002
	Unable to carry on normal activity	3.05	[1.35 - 6.89]	0.007	
	90-80	2.09	[1.28 - 3.41]	0.003	
First graft relapse	No	1.00			0.049
	No previous graft	2.49	[1.08 - 5.73]	0.032	
	Yes	2.13	[0.87 - 5.22]	0.098	
No of lines before alloSCT	>2	1.00			0.084
	1 or 2	0.70	[0.47 - 1.04]	0.080	
HLA match	HLA mismatched	1.00			0.10
	HLA matched	0.68	[0.43 - 1.07]	0.092	

Sex of donnor-patient	Others	1.00			0.027
	F/M	1.61	[1.07 - 2.42]	0.022	
CMV serostatus of donnor patient	neg/neg	1.00			0.78
	Others	0.94	[0.63 - 1.42]	0.78	
Source of stem cells	BM	1.00			0.016
	CB	1.71	[0.91 - 3.21]	0.094	
	PB	0.77	[0.47 - 1.27]	0.31	
Conditionning intensity	MAC	1.00			0.98
	NMA	0.94	[0.48 - 1.83]	0.85	
	RIC	0.98	[0.65 - 1.48]	0.92	
Depletion	No	1.00			0.87
	Partial T depletion	1.12	[0.28 - 4.55]	0.87	
Agvhd grade 3-4		2.82	[1.78 - 4.47]	<0.0001	<0.0001
Cgvhd		1.44	[0.86 - 2.41]	0.16	0.17

Table 6: Univariate analysis of 5 years OS survival

V1	Variable	HR (95%CI)	P
Agvhd	Grade 3-4 Agvhd	2.52 (1.52–4.19)	0.0003
Sex of donnor-patient	F/M	1.33 (0.85–2.08)	0.22
Disease status at transplant	PR	0.83 (0.50–1.36)	0.46
	PD	1.58 (0.88–2.84)	0.13
Karnofsky score	Unable to carry on normal activity	3.16 (1.32–7.61)	0.010
	90-80	2.22 (1.32–3.71)	0.002
Stem cell source	CB	2.01 (1.00–4.01)	0.049
	PB	0.97 (0.56–1.65)	0.90

Table 7: Multivariate analysis of 5 years OS (stratified on the delay between diagnosis and alloSCT)

variable	Variable	HR	IC	pval	p
Age at graft		1.00	[0.99 - 1.01]	0.87	0.86
subtypes	NOS	1.00			0.23
	AITL	1.10	[0.73 - 1.68]	0.64	
	ALCL	0.91	[0.54 - 1.53]	0.73	
	ATLL	2.08	[1.13 - 3.84]	0.019	
	NK/T nasal	1.60	[0.81 - 3.16]	0.18	
	Others	1.22	[0.55 - 2.7]	0.62	
Delay between diag and allo SCT	NO	1.00			0.63
	Yes	0.92	[0.66 - 1.29]	0.63	
Stage at diagnosis	I	1.00			0.94
	II	0.89	[0.31 - 2.57]	0.83	
	III	1.07	[0.44 - 2.61]	0.89	
	IV	1.11	[0.48 - 2.56]	0.81	
Disease status at transplant	CR	1.00			0.057
	PR	1.24	[0.85 - 1.83]	0.27	
	PD	1.90	[1.14 - 3.16]	0.014	
Karnofsky score	100	1.00			0.24
	Unable to carry on normal activity	1.55	[0.61 - 3.93]	0.35	
	90-80	1.36	[0.93 - 1.98]	0.11	
First graft relapse	No	1.00			0.59
	No previous graft	1.30	[0.71 - 2.37]	0.40	
	Yes	1.13	[0.58 - 2.2]	0.72	
No of lines before alloSCT	>2	1.00			0.082
	1 or 2	0.73	[0.51 - 1.04]	0.078	
HLA match	HLA mismatched	1.00			0.077
	HLA matched	0.69	[0.47 - 1.03]	0.067	
Sex of donnor-patient	Others	1.00			0.10
	F/M	1.37	[0.95 - 1.99]	0.093	

CMV serostatus of donor patient	neg/neg	1.00			0.83
	Others	1.04	[0.72 - 1.5]	0.83	
Source of stem cells	BM	1.00			0.036
	CB	1.90	[1.06 - 3.42]	0.031	
	PB	0.99	[0.63 - 1.57]	0.98	
Conditioning intensity	MAC	1.00			0.70
	NMA	1.17	[0.64 - 2.16]	0.61	
	RIC	1.16	[0.81 - 1.67]	0.42	
Depletion	No	1.00			0.18
	Partial T depletion	2.13	[0.79 - 5.78]	0.14	

Table 8: Univariate analysis of 5 years GRFS

V1	Variable	HR (95%CI)	P
Subtypes	AITL	1.22 (0.79–1.89)	0.37
	ALCL	0.91 (0.53–1.54)	0.72
	ATLL	1.89 (1.01–3.52)	0.046
	NK/T nasal	1.76 (0.89–3.50)	0.10
	Others	1.20 (0.54–2.67)	0.66
Disease status at transplant	PR	1.30 (0.86–1.96)	0.21
	PD	2.02 (1.20–3.41)	0.008
Source of stem cells	CB	2.07 (1.10–3.87)	0.023
	PB	1.04 (0.65–1.66)	0.87

Table 9: Multivariate analysis of 5 years GRFS

variable	Variable	HR	IC	pval	p
Age at graft		1.01	[0.99 - 1.02]	0.45	0.45
subtypes	NOS	1.00			0.32
	AITL	1.02	[0.65 - 1.62]	0.93	
	ALCL	1.01	[0.57 - 1.77]	0.98	
	ATLL	2.02	[1.04 - 3.94]	0.038	
	NK/T nasal	1.76	[0.86 - 3.63]	0.12	
	Others	1.01	[0.43 - 2.38]	0.98	
Delay between diag and allo SCT > 12 mo	NO	1.00			0.40
	Yes	0.85	[0.59 - 1.23]	0.40	
Stage at diagnosis	I	1.00			0.84
	II	0.63	[0.2 - 1.96]	0.43	
	III	0.76	[0.31 - 1.9]	0.56	
	IV	0.69	[0.3 - 1.61]	0.39	
Disease status at transplant	CR	1.00			0.088
	PR	1.23	[0.82 - 1.85]	0.32	
	PD	1.92	[1.1 - 3.37]	0.022	
Karnofsky score	100	1.00			0.004
	Unable to carry on normal activity	1.31	[0.46 - 3.76]	0.62	
	90-80	2.04	[1.3 - 3.18]	0.002	
First graft relapse	No	1.00			0.17
	No previous graft	1.75	[0.88 - 3.48]	0.11	
	Yes	1.37	[0.64 - 2.94]	0.41	
No of lines before alloSCT	>2	1.00			0.12
	1 or 2	0.73	[0.5 - 1.08]	0.12	
HLA match	HLA mismatched	1.00			0.058
	HLA matched	0.65	[0.43 - 1]	0.048	
Sex of donnor-patient	Others	1.00			0.44
	F/M	1.18	[0.78 - 1.77]	0.44	

CMV serostatus of donor patient	neg/neg	1.00			0.97
	Others	0.99	[0.67 - 1.47]	0.97	
Source of stem cells	BM	1.00			0.036
	CB	1.96	[1.04 - 3.7]	0.039	
	PB	0.96	[0.58 - 1.59]	0.89	
Conditioning intensity	MAC	1.00			0.43
	NMA	0.75	[0.37 - 1.55]	0.44	
	RIC	1.15	[0.78 - 1.7]	0.49	
Depletion	No	1.00			0.056
	Partial T depletion	3.16	[1.16 - 8.59]	0.025	
Agvhd grade 3-4		2.09	[1.31 - 3.34]	0.002	0.004
Cgvhd		1.56	[0.93 - 2.64]	0.094	0.10

Table 10: Univariate analysis of 5 years EFS

V1	Variable	HR (95%CI)	<i>P</i>
N of lines	1 or 2	0.70 (0.46–1.05)	0.086
Karnofsky score	Unable to carry on normal activity	1.52 (0.53–4.39)	0.44
	90-80	2.24 (1.41–3.56)	0.0006
Cell source	CB	1.99 (0.97–4.05)	0.059
	PB	1.00 (0.58–1.73)	0.99

Table 11: Multivariate analysis of 5 years EFS

variable	Variable	HR	IC	pval	p
Age at graft					0.017
subtypes	NOS	1.02	[1 - 1.05]	0.022	0.28
	AITL	1.00			
	ALCL	1.87	[1.03 - 3.38]	0.039	
	ATLL	1.20	[0.54 - 2.64]	0.66	
	NK/T nasal	1.31	[0.39 - 4.43]	0.67	
	Others	1.68	[0.57 - 4.94]	0.35	
Delay between diag and allo SCT > 12 mo	NO	2.42	[0.97 - 6.06]	0.059	0.76
	Yes	1.00			
Stage at diagnosis	I	0.93	[0.57 - 1.5]	0.76	0.47
	II	1.00			
	III	0.48	[0.08 - 2.9]	0.43	
	IV	1.31	[0.38 - 4.54]	0.67	
Disease status at transplant	CR	0.93	[0.28 - 3.04]	0.90	0.33
	PR	1.00			
	PD	0.86	[0.48 - 1.53]	0.60	
Karnofsky score	100	1.59	[0.79 - 3.18]	0.19	0.040
	Unable to carry on normal activity	1.00			
	90-80	2.30	[0.75 - 6.98]	0.14	
First graft relapse	No	2.04	[1.12 - 3.73]	0.020	0.014
	No previous graft	1.00			
	Yes	4.33	[1.05 - 17.9]	0.043	
No of lines before alloSCT	>2	5.57	[1.3 - 23.76]	0.020	0.055
	1 or 2	1.00			
HLA match	HLA mismatched	0.61	[0.37 - 1]	0.052	0.46
	HLA matched	1.00			
Sex of donnor-patient	Others	0.80	[0.44 - 1.43]	0.45	0.026
	F/M	1.00			
		1.80	[1.09 - 2.98]	0.022	

CMV serostatus of donnor patient	neg/neg	1.00		0.99
	Others	1.00	[0.6 - 1.69]	0.99
Source of stem cells	BM	1.00		0.21
	CB	1.29	[0.57 - 2.91]	0.54
	PB	0.71	[0.39 - 1.31]	0.27
Conditionning intensity	MAC	1.00		0.29
	NMA	1.79	[0.83 - 3.85]	0.14
	RIC	1.38	[0.79 - 2.43]	0.26
Depletion	No	1.00		0.92
	Partial T depletion	0.90	[0.12 - 6.49]	0.92

Table 12: Univariate analysis of 5 years cause specific mortality : HSCT related

V1	Variable	HR (95%CI)	<i>P</i>
Sex of donnor-patient	F/M	1.87 (1.07–3.28)	0.027
Karnofsky score	Unable to carry on normal activity	2.52 (0.82–7.78)	0.11
	90-80	2.03 (1.08–3.83)	0.029
Age at graft		1.02 (1.00–1.04)	0.084

Table 13: Multivariate analysis of 5 years cause specific mortality : HSCT related (stratified on numbers of lines before alloSCT)

Variable	HR	IC	pval	p
MAC	1.00			0.55
RIC/NMA	0.68	[0.17 - 2.7]	0.59	

Table 14: Propensity score for 5 years OS

Variable	HR	IC	pval	p
MAC	1.00			0.93
RIC/NMA	1.06	[0.29 - 3.88]	0.93	

Table 15: Propensity score for 5 years EFS

Variable	HR	IC	pval	p
MAC	1.00			0.72
RIC/NMA	0.72	[0.14 - 3.7]	0.69	

Table 16: Propensity score for 5 years HCST related death

Variables	HR	IC	pval
MAC	1		
RIC/NMA	1.4	[0.27 - 7.22]	0.69

Table 17: Propensity score for 5 years relapse relapse (competitive risks)